Wockhardt's Covid vaccine supply deal with UK Govt extended for 6 months

The drug firm said it has been awarded a six-month extension of its agreement with the UK government

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representational image
Press Trust of India New Delhi
2 min read Last Updated : Feb 10 2021 | 3:41 PM IST

Drug firmWockhardt on Wednesday said it has been awarded a six-month extension of its agreement with the UK government to fill-finishCOVID-19 vaccines.

This expands the original agreement untilAugust 2022, and the manufacturing will continue to be undertaken at the company's North Wales-based subsidiary CP Pharmaceuticals, Wockhardt said in a regulatory filing.

On the development,UK International Trade Secretary Liz Truss said, "It brings important investment to the local area, bringing jobs and security to the community as we battle this awful pandemic".

Wockhardt's investment shows "the strength of our trading ties with India which is a further boost to our already-strong vaccine supply as we build back stronger from coronavirus", she added.

UK Business Secretary Kwasi Kwarteng said it will ensure uninterrupted fill and finish capacity for the UK.

"By extending our contract with Wockhardt, we will ensure the UK has uninterrupted fill and finishcapacity, guaranteeing we have sufficient supplies to protect the British public in the long term," he said.

"We are happy to extend our collaboration with the UK Government to make vaccines available and the arrangement brings in a huge sense of purpose and pride, it upholds our ongoing global commitment to fight against an unprecedented pandemic", Wockhardt Group Founder Chairman Habil Khorakiwala said.

Wockhardt in August 2020 had said in a regulatory filing that it had entered into an agreement with the UK government to fill-finish the COVID-19 vaccines.

Shares of Wockhardt were trading at Rs527.15on BSE, up 1.47 per cent from the previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusWockhardtCoronavirus Vaccine

First Published: Feb 10 2021 | 3:38 PM IST

Next Story